As epigenetic readers modulating the transcription of several cancer‐related genes, BET proteins are considered potential therapeutic targets in many cancer types, such as acute myeloid leukemia (AML) [12] and NUT midline carcinoma (NMC) [13, 14], and the identification of inhibitory mechanisms and/or drugs able to suppress BET pathways is currently a hot topic in cancer research. This evidence concerns the gene DNER and acute myeloid leukemia.